Kim Janda - 27 Sep 2021 Form 4 Insider Report for Sorrento Therapeutics, Inc. (SRNEQ)

Role: Director
Signature: /s/ Henry Ji, Ph.D., as Attorney-in-Fact
Issuer symbol: SRNEQ
Transactions as of: 27 Sep 2021
Net transactions value: -$250,456
Form type: 4
Filing time: 28 Sep 2021, 17:37:34 UTC
Previous filing: 14 Sep 2021
Next filing: 27 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SRNEQ	Common Stock	Options Exercise	$63,000	+35,000	+1167%	$1.80	38,000	27 Sep 2021	Direct	F1
transaction	SRNEQ	Common Stock	Options Exercise	$26,264	+7,357	+19%	$3.57	45,357	27 Sep 2021	Direct	F1
transaction	SRNEQ	Common Stock	Sale	$339,720	-42,357	-93%	$8.02	3,000	27 Sep 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SRNEQ	Stock Options	Options Exercise	$0	-35,000	-100%	$0.000000^*	0	27 Sep 2021	Common Stock	35,000	$1.80	Direct	F1, F3
transaction	SRNEQ	Stock Options	Options Exercise	$0	-7,357	-21%	$0.000000	27,643	27 Sep 2021	Common Stock	7,357	$3.57	Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.03, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.
F3	1/12 of the original number of shares subject to this option vested and became exercisable on October 15, 2017 and 1/12 of the original number of shares subject to the option vested following each one month of service thereafter.
F4	1/12 of the original number of shares subject to this option vested and became exercisable on December 26, 2018 and 1/12 of the original number of shares subject to the option vested following each one month of service thereafter.